Income Taxes (Details) - USD ($) $ in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2018 |
|
| Income Taxes [Line Items] | |||
| U.S. statutory federal income tax rate | 21.00% | 21.00% | |
| Valuation allowance | $ 3,860 | $ 3,540 | |
| Capitalized value | 3,215 | 4,416 | |
| Amortization deductions | 2,370 | 1,850 | |
| Capitalized research and development costs | 2,547 | 3,183 | |
| Operating loss carryforwards | $ 85,863 | $ 62,864 | |
| Percentage of future taxable income | 80.00% | ||
| Carryforwards term | 20 years | ||
| Federal and state research and development credits | $ 877 | 708 | |
| Percentage of ownership | 50.00% | ||
| Federal [Member] | |||
| Income Taxes [Line Items] | |||
| Operating loss carryforwards | 78,165 | ||
| Post-Apportioned Massachusetts [Member] | |||
| Income Taxes [Line Items] | |||
| Operating loss carryforwards | $ 82,240 | 74,656 | |
| Research and Development Expense [Member] | |||
| Income Taxes [Line Items] | |||
| Federal and state research and development credits | $ 1,772 | $ 1,483 | |
| Tax Year 2037 [Member] | |||
| Income Taxes [Line Items] | |||
| Operating loss carryforwards | $ 22,999 | ||
| X | ||||||||||
- Definition Carryforwards term. No definition available.
|
| X | ||||||||||
- Definition The amount of federal and state research and development credits. No definition available.
|
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax liability attributable to taxable temporary differences from research and development costs. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Percentage of domestic federal statutory tax rate applicable to pretax income (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|